USBC increases at-the-market offering to $14.5 million on NYSE American

USBC (formerly Know Labs, Inc.) expanded its at-the-market equity offering program to $14.5 million for general corporate purposes, following shareholder approval to significantly increase authorized shares from 7.5 million to 750 million. This capital raise comes amidst the company's weak financial health and an 88% year-to-date share price decline. Notably, USBC is slated for acquisition by Goldeneye 1995 LLC in Q3 2025 at a share price of $0.335, which is substantially below its current trading price of $0.84, highlighting a significant arbitrage opportunity or considerable uncertainty surrounding the deal's completion.

Analysis

USBC, Inc. (formerly Know Labs) presents a deeply distressed financial profile coupled with significant event-driven uncertainty. The company is actively raising capital through an expanded at-the-market (ATM) offering, now totaling $14.5 million, which follows a shareholder-approved 100-fold increase in authorized shares from 7.5 million to 750 million. These actions underscore a critical need for liquidity, consistent with its weak financial health score of 1.26 out of 10 and a catastrophic 88% year-to-date decline in share price. The most salient feature is the stark discrepancy between its current trading price of $0.84 and the $0.335 per share price in its pending acquisition by Goldeneye 1995 LLC, expected to close in Q3 2025. This ~150% premium to the deal price suggests the market is pricing in a very high probability that the acquisition will either fail, be significantly renegotiated, or that its complex terms—which include a formula based on 1,000 Bitcoin—introduce extreme volatility and risk.

Key Decisions for Investors

• Investors should recognize the extreme downside risk, as the current stock price of $0.84 is trading at a significant premium to the agreed-upon acquisition price of $0.335, implying a high probability of deal failure or adverse restructuring.
• The ongoing at-the-market offering and massive increase in authorized shares signal severe and continuing shareholder dilution; positions should be evaluated in the context of this eroding equity value and the company's weak underlying fundamentals.
• Monitor all SEC filings and news related to the Goldeneye 1995 LLC acquisition for any signs of progress or termination, as the deal's outcome is the primary driver of valuation and the key catalyst for resolving the current price dislocation.